Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

摘要: Background: EGFR and KRAS mutations are mutually exclusive predict outcomes with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in patients stage IV lung cancers. The clinical significance of these resected I–III cancers is unclear. Methods: At our institution, resection specimens from adenocarcinomas tested for the presence or during routine pathology analysis such that results available before consideration adjuvant therapy. In a cohort 1118 over 8 years, overall survival was analyzed using multivariate to control potential confounders, including age, sex, stage, smoking history. impact erlotinib gefitinib examined an independent data set exclusively mutation, which date recurrence recorded. Results: population, we identified 227 (25%) 222 (20%) mutations. Patients -mutant had lower risk death compared those without mutations, (OS) HR 0.51 (95% confidence interval [CI]: 0.34–0.76, p similar individuals wild-type tumors, OS 1.17 CI: 0.87–1.57, = 0.30). A separate includes only 10 years ( n 286). associated death, disease-free 0.43 0.26–0.72, 0.001), trend toward improved OS. Conclusions: mutation have mutation. This may be because TKIs. with, These support reflex testing provide prognostic information identify enrollment on prospective trials